52 minutes ago | News
Watson Pharmaceuticals CEO Paul Bisaro said the company has around $6 billion to spend on acquisitions as it looks to buy brand-name drug assets, signaling a move away from the company's focus on generic medicines, Bloomberg reported Thursday.
|
Feb 7 | News
NEW YORK (AP) — Shares of Anacor Pharmaceuticals Inc. dropped more than 8 percent Monday after the company said its partner GlaxoSmithKline PLC stopped enrolling patients in studies of an anti-infection drug.
|
Feb 7 | News
SAN DIEGO (AP) — Diabetes drug maker Amylin Pharmaceuticals Inc. reported a larger fourth-quarter loss Monday after it ended a partnership with Eli Lilly & Co., which gave Amylin all the rights to the drug Byetta and newly approved Bydureon.
|
Feb 7 | News
LONDON (AP) — GlaxoSmithKline PLC says it has returned to profit in the fourth quarter as restructuring costs and overheads declined.
|
Feb 6 | News
NEW YORK (AP) — Shares of Gilead Sciences Inc. jumped Friday after the company reported further progress of GS-7977, a newly-acquired hepatitis C treatment still in clinical testing.
|
Feb 3 | News
MONTREAL — Montreal's pharmaceutical research cluster is under further threat as global giants adjust to the loss of patent protection for blockbuster drugs and challenges in developing replacements.
|
Feb 3 | News
Alkermes PLC's fiscal third-quarter loss widened as operating expenses ballooned compared to the previous year's quarter, before the company had completed its acquisition of Elan Corp.'s drug technology business.
|
Feb 3 | News
MannKind Corporation today announced that it has entered into a purchase agreement with The Mann Group LLC, an entity controlled by MannKind's chief executive officer and principal stockholder, Alfred E. Mann, for the sale of shares of its common stock to The Mann Group.
|
Feb 2 | News
LONDON (AP) — AstraZeneca PLC said it will cut another 7,300 jobs as it warned today of a tough year ahead, due to government spending cuts on healthcare and stiff competition, even as it reported a 24 percent increase in 2011 profits.
|
Feb 2 | News
WHITEHOUSE STATION, N.J. (AP) — Merck & Co. said today that it swung to a fourth-quarter profit because of lower acquisition and restructuring charges and slightly higher sales.
|